Christopher Eberle, DPM
Podiatrist · Mishawaka, INNPI 1689200552
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,175 of the $5,974 with a category attached, or 69.9%. Stryker accounts for 87.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $3,868 and has fallen 53.5% since, to $1,798 in 2025.
Across 69 payments — averaging $86.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$5K
- Mimedx Group, Inc.$269
- Reapplix Inc.$127
- Kerecis Limited$119
- Organogenesis Inc.$30
- AbbVie$27
- plus $164 from 9 others
What the payments were for
- Travel & lodging$4,17570%
- Food & beverage$1,79930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 52 | $5,238 |
| Mimedx Group, Inc. | 3 | $269 |
| Reapplix Inc. | 1 | $127 |
| Kerecis Limited | 2 | $119 |
| Organogenesis Inc. | 1 | $30 |
| AbbVie | 1 | $27 |
| Nevro Corp. | 1 | $26 |
| Integra Lifesciences Corporation | 1 | $24 |
| Treace Medical Concepts, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| KCI USA, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
| Orthofix Medical, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROstep$2,981
- PROPHECY$1,128
- INFINITY$570
- AUGMENT INJECTABLE$144
- 3C Patch Kit - Box$127
- EPI LINE PRODUCTS ALL EPI$114
How this compares
$5,974 in reported general payments places this provider in the 75th percentile of 131 podiatrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terbinafine Hcl | 31 | $277 |
| Ammonium Lactate | 18 | $260 |
| Doxycycline Hyclate | 17 | $185 |
| Cephalexin | 14 | $101 |
| Methylprednisolone | 11 | $62 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $50 |
| Gabapentin | 16 | $46 |
| Meloxicam | 22 | $34 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Mishawaka
- Jason GroveMishawaka$7K
- Micah SpencerMishawaka$6K
- Andrew RaderJasper$726K
- Anthony MillerIndianapolis$292K
- Corey GrohIndianapolis$57K
- Jeffrey StevensIndianapolis$56K
- James VestileTipton$44K
- Andrew KapsalisAvon$37K
- Scott HoffmanAvon$22K
- John RachoyMunster$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.